The European Medicines Agency (EMA) convened its 13th Industry Standing Group (ISG) meeting on June 30, 2025, addressing pivotal updates and future directives aimed at strengthening the pharmaceutical landscape within the European Union. Chaired by Juan Garcia Burgos, the session focused on key legislative proposals, product management enhancements, and collaborative efforts to ensure the availability and safety of critical medicines.
Critical Medicines Act Proposal Presented
During the meeting, EMA presented the Commission’s proposal for the Critical Medicines Act (CMA), which incorporates extensive feedback from stakeholders through structured dialogues and critical medicines alliances. The CMA is designed to secure the supply and accessibility of essential medicines by reinforcing four main pillars. Currently under review by the European Parliament and the Council of the European Union, the act awaits progression to the trilogue stage. Industry stakeholders expressed support while seeking further guidance on implementation strategies, particularly for specialized products like blood and plasma-derived medicines. EMA emphasized the importance of accurate product data to minimize redundancies and streamline processes.
Advancements in Product Management and Regulatory Processes
The ISG also received an update on the Product Management Service (PMS), highlighting the integration of master data and interoperability as critical priorities. EMA outlined the phased approach for incorporating PMS data into all regulatory submissions, aligning with the revised pharmaceutical legislation. Additionally, the meeting covered the activities of medical devices expert panels, the regulatory/HTA interface under the HTA Regulation, and the impact of REACH on the healthcare industry. These discussions underscore EMA’s commitment to enhancing regulatory frameworks and fostering innovation within the sector.
• EMA’s CMA aims to ensure uninterrupted supply of critical medicines.
• Stakeholders seek clear guidelines for implementing the CMA, especially for specialized products.
• Accurate data management in PMS is crucial for regulatory efficiency.
• Enhanced collaboration between EMA and HTA secretariats is necessary for seamless regulatory assessments.
EMA’s comprehensive approach during the ISG meeting reflects a proactive stance in addressing current challenges and anticipating future needs within the pharmaceutical industry. By prioritizing data accuracy, stakeholder collaboration, and robust legislative frameworks, EMA is poised to significantly improve the availability and safety of medicines across the European Union. Industry stakeholders can look forward to more detailed guidance and continued engagement from EMA as these initiatives progress, ensuring that both regulatory bodies and manufacturers are well-equipped to meet evolving demands.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
